CoChat
Sign Up
Cited by 186

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

An Evaluation of Blood Compatibility of Silver Nanoparticles

Huang, He, Lai, Wenjia, Cui, Menghua, Liang, Ling, Lin, Yuchen, Fang, Qiaojun, Liu, Ying, Xie, Liming·2016·Scientific Reports
DOI 10.1038/srep25518PMC PMC4857076
Open this paper in CoChat — free account

Abstract

Silver nanoparticles (AgNPs) have tremendous potentials in medical devices due to their excellent antimicrobial properties. Blood compatibility should be investigated for AgNPs due to the potential blood contact. However, so far, most studies are not systematic and have not provided insights into the mechanisms for blood compatibility of AgNPs. In this study, we have investigated the blood biological effects, including hemolysis, lymphocyte proliferation, platelet aggregation, coagulation and complement activation, of 20 nm AgNPs with two different surface coatings (polyvinyl pyrrolidone and citrate). Our results have revealed AgNPs could elicit hemolysis and severely impact the proliferation and viability of lymphocytes at all investigated concentrations (10, 20, 40 μg/mL). Nevertheless, AgNPs didn’t show any effect on platelet aggregation, coagulation process, or complement activation at up to ~40 μg/mL. Proteomic analysis on AgNPs plasma proteins corona has revealed that acidic and small molecular weight blood plasma proteins were preferentially adsorbed onto AgNPs, and these include some important proteins relevant to hemostasis, coagulation, platelet, complement activation and immune responses. The predicted biological effects of AgNPs by proteomic analysis are mostly consistent with our experimental data since there were few C3 components on AgNPs and more negative than positive factors involving platelet aggregation and thrombosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep25518

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 78

  1. Leucuta, S. E. Nanotechnology for delivery of drugs and biomedical applications. Curr. Clin. Pharmacol. 5, 257–280 (2010). · DOI
  2. Chaloupka, K., Malam, Y. & Seifalian, A. M. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol. 28, 580–588 (2010). · DOI
  3. Lansdown, A. B. A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv. Pharmacol. Sci. 2010, 910686; 10.1155/2010/910686 (2010). · DOI
  4. Ahamed, M., Alsalhi, M. S. & Siddiqui, M. K. Silver nanoparticle applications and human health. Clin. Chim. Acta 411, 1841–1848 (2010). · DOI
  5. Beer, C., Foldbjerg, R., Hayashi, Y., Sutherland, D. S. & Autrup, H. Toxicity of silver nanoparticles - nanoparticle or silver ion? Toxicol. Lett. 208, 286–292 (2012). · DOI
  6. Elechiguerra, J. L. et al. Interaction of silver nanoparticles with HIV-1. J. Nanobiotech. 3, 6 10.1186/1477-3155-3-6 (2005). · DOI
  7. Tian, J. et al. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2, 129–136 (2007). · DOI
  8. Wong, K. K. et al. Further evidence of the anti-inflammatory effects of silver nanoparticles. ChemMedChem 4, 1129–1135 (2009). · DOI
  9. Kalishwaralal, K., BarathManiKanth, S., Pandian, S. R. K., Deepak, V. & Gurunathan, S. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis . Colloid Surface B 79, 340–344 (2010). · DOI
  10. Chen, X. & Schluesener, H. J. Nanosilver: A nanoproduct in medical application. Toxicol. Lett. 176, 1–12 (2008). · DOI
  11. Sung, J. H. et al. Subchronic inhalation toxicity of silver nanoparticles. Toxicol. Sci. 108, 452–461 (2009). · DOI
  12. Laloy, J. et al. Impact of silver nanoparticles on haemolysis, platelet function and coagulation. Nanobiomedicine 1, 10.5772/59346 (2014). · DOI
  13. BS EN ISO 10993-4:2009 Biological evaluation of medical devices. Part 4: Selection of tests for interactions with blood. 10.3403/30194461U (2010). · DOI
  14. Arzoumanian, L. What is hemolysis, what are the causes, what are the effects? BD Tech Talk 2, 1–3 (2003).
  15. Dobrovoiskaia, M. A. et al. Method for analysis of nanoparticle hemolytic properties in vitro . Nano Lett. 8, 2180–2187 (2008). · DOI
  16. Delvaeye, M. & Conway, E. M. Coagulation and innate immune responses: can we view them separately? Blood 114, 2367–2374 (2009). · DOI
  17. Jun, E. A. et al. Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity. Nanotoxicology 5, 157–167 (2011). · DOI
  18. Krajewski, S. et al. Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop in vitro assay on human blood. Acta Biomater. 9, 7460–7468 (2013). · DOI
  19. Choi, J., Reipa, V., Hitchins, V. M., Goering, P. L. & Malinauskas, R. A. Physicochemical characterization and in vitro hemolysis evaluation of silver nanoparticles. Toxicol. Sci. 123, 133–143 (2011). · DOI
  20. Shrivastava, S. et al. Characterization of antiplatelet properties of silver nanoparticles. ACS Nano 3, 1357–1364 (2009). · DOI
  21. Stevens, K. N. J. et al. The relationship between the antimicrobial effect of catheter coatings containing silver nanoparticles and the coagulation of contacting blood. Biomaterials 30, 3682–3690 (2009). · DOI
  22. Shrivastava, S. et al. Negative regulation of fibrin polymerization and clot formation by nanoparticles of silver. Colloid Surface B 82, 241–246 (2011). · DOI
  23. Martinez-Gutierrez, F. et al. Antibacterial activity, inflammatory response, coagulation and cytotoxicity effects of silver nanoparticles. Nanomedicine 8, 328–336 (2012). · DOI
  24. Meng, J. et al. Using gold nanorods core/silver shell nanostructures as model material to probe biodistribution and toxic effects of silver nanoparticles in mice. Nanotoxicology 8, 686–696 (2014). · DOI
  25. Bandyopadhyay, D., Baruah, H., Gupta, B. & Sharma, S. Silver nano particles prevent platelet adhesion on immobilized fibrinogen. Indian J. Clin. Biochem. 27, 164–170 (2012). · DOI
  26. Deb, S. et al. Surface tunability of nanoparticles in modulating platelet functions. Blood Cells Mol. Dis. 48, 36–44 (2012). · DOI
  27. Yu, K. et al. Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. ACS Nano 8, 7687–7703 (2014). · DOI
  28. De Paoli, S. H. et al. The effect of protein corona composition on the interaction of carbon nanotubes with human blood platelets. Biomaterials 35, 6182–6194 (2014). · DOI
  29. Wolfram, J. et al. The nano-plasma interface: Implications of the protein corona. Colloid Surface B 124, 17–24 (2014). · DOI
  30. Xu, Y. et al. Complement activation in factor D-deficient mice. Proc. Natl. Acad. Sci. USA 98, 14577–14582 (2001). · DOI · Paper page
  31. Janssen, B. J. et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437, 505–511 (2005). · DOI
  32. Liu, W. et al. Protein corona formation for nanomaterials and proteins of a similar size: hard or soft corona? Nanoscale 5, 1658–1668 (2013). · DOI
  33. Winzen, S. et al. Complementary analysis of the hard and soft protein corona: sample preparation critically effects corona composition. Nanoscale 7, 2992–3001 (2015). · DOI
  34. Mohanty, S. et al. An investigation on the antibacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles. Nanomedicine 8, 916–924 (2012). · DOI
  35. Kwon, T. et al. Optimizing hemocompatibility of surfactant-coated silver nanoparticles in human erythrocytes. J. Nanosci. Nanotechno. 12, 6168–6175 (2012). · DOI
  36. Sopjani, M., Foller, M., Haendeler, J., Gotz, F. & Lang, F. Silver ion-induced suicidal erythrocyte death. J. Appl. Toxicol. 29, 531–536 (2009). · DOI
  37. Li, S. Q. et al. Nanotoxicity of TiO2 nanoparticles to erythrocyte in vitro . Food Chem. Toxicol. 46, 3626–3631 (2008). · DOI
  38. Ivask, A. et al. Toxicity mechanisms in Escherichia coli vary for silver nanoparticles and differ from ionic silver. ACS Nano 8, 374–386 (2014). · DOI
  39. Almofti, M. R., Ichikawa, T., Yamashita, K., Terada, H. & Shinohara, Y. Silver ion induces a cyclosporine a-insensitive permeability transition in rat liver mitochondria and release of apoptogenic cytochrome C. J. Biochem. 134, 43–49 (2003). · DOI
  40. Wataha, J. C., Lockwood, P. E., Schedle, A., Noda, M. & Bouillaguet, S. Ag, Cu, Hg and Ni ions alter the metabolism of human monocytes during extended low-dose exposures. J. Oral Rehabil. 29, 133–139 (2002). · DOI
  41. AshaRani, P. V., Low Kah Mun, G., Hande, M. P. & Valiyaveettil, S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3, 279–290 (2009). · DOI
  42. Greulich, C. et al. Cell type-specific responses of peripheral blood mononuclear cells to silver nanoparticles. Acta Biomater. 7, 3505–3514 (2011). · DOI
  43. Park, E. J., Yi, J., Kim, Y., Choi, K. & Park, K. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. Toxicol. In Vitro 24, 872–878 (2010). · DOI
  44. Kim, J. S. et al. Genotoxicity, acute oral and dermal toxicity, eye and dermal irritation and corrosion and skin sensitisation evaluation of silver nanoparticles. Nanotoxicology 7, 953–960 (2013). · DOI
  45. Hyun-Jeong, E., Nivedita, C., Jeongsoo, L. & Jinhee, C. Integrated mRNA and micro RNA profiling reveals epigenetic mechanism of differential sensitivity of Jurkat T cells to AgNPs and Ag ions. Toxicol. Lett. 229, 311–318 (2014). · DOI
  46. Parnsamut, C. & Brimson, S. Effects of silver nanoparticles and gold nanoparticles on IL-2, IL-6, and TNF-alpha production via MAPK pathway in leukemic cell lines. Genet. Mol. Res. 14, 3650–3668 (2015). · DOI
  47. van der Zande, M. et al. Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. ACS Nano 6, 7427–7442 (2012). · DOI
  48. Gengan, R. M., Anand, K., Phulukdaree, A. & Chuturgoon, A. A549 lung cell line activity of biosynthesized silver nanoparticles using Albizia adianthifolia leaf. Colloid Surface B 105, 87–91 (2013). · DOI
  49. Ragaseema, V. M., Unnikrishnan, S., Kalliyana Krishnan, V. & Krishnan, L. K. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. Biomaterials 33, 3083–3092 (2012). · DOI
  50. Krishnaraj, R. N. & Berchmans, S. In vitro antiplatelet activity of silver nanoparticles synthesized using the microorganism Gluconobacter roseus: an AFM-based study. RSC Adv. 3, 8953–8959 (2013). · DOI
  51. Park, K. Toxicokinetic differences and toxicities of silver nanoparticles and silver ions in rats after single oral administration. J. Toxicol. Environ. Health A 76, 1246–1260 (2013). · DOI
  52. Nel, A. E. et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543–557 (2009). · DOI · Paper page
  53. Treuel, L., Docter, D., Maskos, M. & Stauber, R. H. Protein corona - from molecular adsorption to physiological complexity. Beilstein J. Nanotechnol. 6, 857–873 (2015). · DOI
  54. Monopoli, M. P., Aberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7, 779–786 (2012). · DOI · Paper page
  55. Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8, 772–781 (2013). · DOI · Paper page
  56. Walkey, C. D. et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8, 2439–2455 (2014). · DOI
  57. Jilma-Stohlawetz, P. et al. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion 41, 378–381 (2001). · DOI
  58. Kawamoto, R. et al. Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population. Cardiovasc. Diabetol. 10, 51, 10.1186/1475-2840-10-51 (2011). · DOI
  59. Nanjappa, V. et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res. 42, D959–965 (2014). · DOI
  60. Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A. & McNeil, S. E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliver. Rev. 61, 428–437 (2009). · DOI · Paper page
  61. Patel, H. M. Serum opsonins and liposomes - their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9, 39–90 (1992).
  62. Brandt, J. T. Current concepts of coagulation. Clin. Obstet. Gynecol. 28, 3–14 (1985). · DOI
  63. Truedsson, L. Classical pathway deficiencies - A short analytical review. Mol. Immunol. 68, 14–19 (2015). · DOI
  64. Revak, S. D., Cochrane, C. G. & Griffin, J. H. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen. J. Clin. Invest. 59, 1167–1175 (1977). · DOI
  65. Gob, E. et al. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann. Neurol. 77, 784–803 (2015). · DOI
  66. Chavakis, T. et al. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen. J. Biol. Chem. 277, 23157–23164 (2002). · DOI
  67. Chavakis, T., Pixley, R. A., Isordia-Salas, I., Colman, R. W. & Preissner, K. T. A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J. Biol. Chem. 277, 32677–32682 (2002). · DOI
  68. Chavakis, T. & Preissner, K. T. Potential pharmacological applications of the antithrombotic molecule high molecular weight kininogen. Curr. Vasc. Pharmacol. 1, 59–64 (2003). · DOI
  69. Vuilleumier, N., Dayer, J. M., von Eckardstein, A. & Roux-Lombard, P. Pro- or anti-inflammatory role of apolipoprotein A-1 in high-density lipoproteins? Swiss Med. Wkly. 143, w13781; 10.4414/smw.2013.13781 (2013). · DOI
  70. Riddell, D. R. & Owen, J. S. Inhibition of ADP-induced platelet aggregation by apoE is not mediated by membrane cholesterol depletion. Thromb. Res. 81, 597–606 (1996). · DOI
  71. Riddell, D. R., Graham, A. & Owen, J. S. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway. Implications for vascular disease. J. Biol. Chem. 272, 89–95 (1997). · DOI · Paper page
  72. Lundqvist, M. et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. USA 105, 14265–14270 (2008). · DOI
  73. McDonald, W. H., Ohi, R., Miyamoto, D. T., Mitchison, T. J. & Yates Iii, J. R. Comparison of three directly coupled HPLC MS/MS strategies for identification of proteins from complex mixtures: single-dimension LC-MS/MS, 2-phase MudPIT, and 3-phase MudPIT. Int. J. Mass spectrom. 219, 245–251 (2002). · DOI
  74. Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896–1906 (2007). · DOI · Paper page
  75. Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011). · DOI
  76. Saito, R. et al. A travel guide to Cytoscape plugins. Nat. Methods 9, 1069–1076 (2012). · DOI
  77. Bindea, G. et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25, 1091–1093 (2009). · DOI · Paper page
  78. Boyle, E. I. et al. GO::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 20, 3710–3715 (2004). · DOI · Paper page

Cited by

Sorted by citations

See all 186

Metadata

Authors
Huang, H., Lai, W., Cui, M., Liang, L., Lin, Y., Fang, Q., Liu, Y., & Xie, L.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2016-05-05
Volume
6
Issue
1
ISSN
2045-2322
DOI
10.1038/srep25518
PMC
PMC4857076
Cited by
186
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review